HOME Research Insight Approvals Was the Most-Preferred Strategy Followed by Key Players in the Biosimilars Market



Approvals Was the Most-Preferred Strategy Followed by Key Players in the Biosimilars Market


Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO) & Application (Oncology, Blood Disorders) - Global Forecast To 2021

Sandoz International GmbH (Germany) was the global leader in the biosimilars market in 2015. The company offers an exhaustive product portfolio comprising various biosimilars products, such as reagents and kits, media, magnetic beads, and centrifuges. The company also focuses on organic growth strategies such as approvals to enhance its market share. For instance, in August 2016, Sandoz received the FDA approval for its biosimilar etanercept (Erelzi), which is used to treat multiple inflammatory diseases such as psoriatic psoriasis (PsA), rheumatoid arthritis (RA), ankylosing spondylitis (AS), plaque psoriasis (PsO), and juvenile idiopathic arthritis (JIA).

Teva Pharmaceutical Industries Ltd. (Israel) held the second position in the biosimilars market in 2015. This can be attributed to the company’s biosimilars products. The company adopts organic growth strategies such as new approvals to boost its market share. For instance, in December 2014, Teva Pharmaceutical received the U.S. Food and Drug Administration (FDA) approval for GRANIX, a tbo-filgrastim injection that is self-administered by patients as well as caregivers, making treatment more flexible.

Pfizer Inc (U.S.) held the third position in the biosimilars market in 2015. The company adopted organic growth strategies such as approval to boost its market share. In June 2016, Hospira Inc., a Pfizer company, received Health Canada approval for its Inflectra (biosimilar infliximab) to treat diseases such as Crohn’s disease (CD), Fistulising Crohn’s disease, and ulcerative colitis (UC).

The key strategies followed by most companies in the biosimilars market are organic strategies such as, approvals. The strategy of approvals accounted for the largest share of the overall growth strategies mapped from 2013 to 2016.

Related Reports:

Biosimilars Market by Product (Recombinant Non-glycosylated Proteins (Insulin, rHGH, Interferon), glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-House, CMO), Application (Oncology, Blood Disorders) - Global Forecast to 2021

Contact:
Mr. Rohan
Markets and Markets 
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune, Maharashtra 411013, India
1-888-600-6441
Email: sales@marketsandmarkets.com

Connect Us

Follow us on LinkedIn  Follow us on Facebook   Follow us on Twitter 
Live Chat Support


US : 1-888-600-6441

Search reports